InSphero

1. Executive Summary (Confidence: High)

InSphero AG, founded in 2009 as a spin-off of ETH Zurich, is the industry standard-bearer for "The Model of Excellence™" in 3D cell culture. Headquartered in Schlieren, Switzerland, the organization provides a suite of advanced microphysiological systems that address the high failure rate of drugs in clinical trials. In November 2025, InSphero significantly expanded its technological moat by acquiring DOPPL SA and its Sun Bioscience Gri3D® technology, effectively merging the scalability of spheroids with the physiological depth of organoids. The company is at the vanguard of the longevity ecosystem, offering immune-competent models and specialized metabolic assays that accelerate the discovery of therapies for age-related conditions like fibrosis and Type 1 Diabetes. With a global distribution network and a laboratory hub in North America, InSphero is a critical partner for the modernization of drug discovery.